INEB-INSTITUTO NACIONAL DE ENGENHARIA BIOMEDICA

Their core work

INEB is Portugal's national biomedical engineering research institute, based in Porto, specializing in biomaterials, nanomedicine, and tissue regeneration — particularly for musculoskeletal conditions like cartilage damage, osteoarthritis, and bone disease. They develop smart nanobiomaterials, 3D bioprinting techniques, and organ-on-chip platforms that bridge the gap between laboratory research and clinical application. Their work combines materials science with biological systems to create targeted therapies, diagnostic tools, and in-vitro models that reduce reliance on animal testing while advancing precision medicine for joint and bone disorders.

What they specialise in

How they've shifted over time

INEB's early H2020 work (2017–2019) centered on fundamental materials — corrosion durability, bone pain mechanisms, and first-generation smart nanobiomaterials for cartilage repair via bioprinting. From 2020 onward, their focus shifted decisively toward precision medicine platforms: organ-on-chip systems, in-silico modeling, omics integration, and clinical-trial-on-chip technologies. The trajectory shows a clear move from developing individual biomaterials toward building integrated diagnostic and therapeutic platforms that combine multiple technologies for personalized treatment of joint and bone diseases.

INEB is converging on integrated precision medicine systems — combining nanomedicine, organ-on-chip, and molecular bioengineering — making them a strong future partner for clinical translation and personalized therapy projects.

How they like to work

INEB primarily participates as a specialist partner (7 of 9 projects), contributing biomaterials and bioengineering expertise to larger consortia, but has demonstrated coordination capacity in two significant projects — RESTORE (EUR 933K, smart nanobiomaterials) and MOBILIsE (EUR 2.5M, ERA Chair). With 86 unique partners across 22 countries, they operate as a well-connected hub rather than a closed network, suggesting they are easy to integrate into new consortia. Their strong MSCA training network participation (4 projects) also signals commitment to researcher mobility and knowledge transfer.

INEB has built a broad European network of 86 unique consortium partners spanning 22 countries, reflecting substantial reach for a Portuguese research institute. Their MSCA training network involvement ensures strong ties to universities and research labs across the EU, particularly in biomedical and materials science communities.

What sets them apart

INEB sits at a rare intersection of materials engineering and biomedical science — they don't just study diseases or just develop materials, they engineer biomaterial-based solutions for specific clinical problems in the musculoskeletal domain. Their ERA Chair investment (MOBILIsE, their largest project at EUR 2.5M) signals an institutional commitment to becoming a European reference point in molecular bioengineering. For consortium builders, INEB offers a combination that is hard to find elsewhere in Southern Europe: deep nanomedicine expertise, hands-on 3D bioprinting capability, and organ-on-chip platform development, all under one roof.

Highlights from their portfolio

• MOBILIsE
  Their largest project (EUR 2.5M) and an ERA Chair grant, signaling EU investment in building INEB into a European leader in molecular bioengineering — a strong institutional credibility marker.
• RESTORE
  Coordinated by INEB, this project combines smart nanobiomaterials with bioprinting and remote-controlled stimuli-responsive systems for cartilage repair — showcasing their ability to lead ambitious interdisciplinary work.
• FLAMIN-GO
  Represents INEB's most advanced platform work: building a synovia-on-chip with microfluidic technology and 3D bioprinting to model rheumatoid arthritis for precision medicine, bridging digital and manufacturing domains.